STOCK MARKET BSE NSE

UK to infect volunteers with COVID-19 in controversial 'challenge' vaccine research trial

The approach, called a challenge study, is risky but proponents say it may produce results faster than standard research.

Published: 20th October 2020 02:19 PM  |   Last Updated: 20th October 2020 02:40 PM   |  A+A-

COVID Vaccine

For representational purposes (Photo | AP)

By Associated Press

LONDON: U.K. researchers are preparing to begin a controversial experiment that will infect healthy volunteers with coronavirus to study the disease in hopes of speeding up the development of a vaccine.

The approach, called a challenge study, is risky but proponents say it may produce results faster than standard research, which waits to see if volunteers who have been given an experimental treatment get sick. The government is preparing to invest 33.6 million pounds ($43.4 million) in the study.

Imperial College London said Tuesday that the study, involving healthy volunteers between 18 and 30, would be conducted in partnership with the Department for Business, Energy and Industrial Strategy, the Royal Free London NHS Foundation Trust and hVivo, a company that has experience conducting testing.

ALSO READ: COVID-19 vaccine storage issues could leave three billion people without access

“Deliberately infecting volunteers with a known human pathogen is never undertaken lightly,'' said Peter Openshaw, co-investigator on the study. “However, such studies are enormously informative about a disease, even one so well studied as COVID-19. ‘’

In the first phase of the study, researchers will aim to determine the smallest level of exposure needed to cause the disease. Researchers will then use the same challenge model to study how potential vaccines work in the body, the body's immune response and potential treatments.

Vaccine Taskforce chair Kate Bingham said the research will improve our understanding of the virus and will help in making decisions about research.

“There is much we can learn in terms of immunity, the length of vaccine protection, and reinfection,'' she said in a statement.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp